Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 9/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4113314 | 1.00 | HSD11B1 (0.42) | HSD11B1POLBEPHX2ALDH1A1LMNA | |
| SCHEMBL4108117 | 0.88 | HSD11B1 (0.40) | HSD11B1POLBEPHX2ALDH1A1LMNA | |
| SCHEMBL4108122 | 0.88 | HSD11B1 (0.40) | HSD11B1POLBEPHX2ALDH1A1LMNA | |
| SCHEMBL4106544 | 0.87 | HSD11B1 (0.41) | HSD11B1POLBEPHX2ALDH1A1LMNA | |
| SCHEMBL4106538 | 0.87 | HSD11B1 (0.41) | HSD11B1POLBEPHX2ALDH1A1LMNA | |
| SCHEMBL4106624 | 0.79 | HSD11B1 (0.65) | HSD11B1POLBEPHX2ALDH1A1LMNA | |
| SCHEMBL5242983 | 0.70 | HSD11B1 (0.40) | HSD11B1EPHX2ALDH1A1LMNAHSD11B2 | |
| SCHEMBL4106627 | 0.69 | EPHX2 (0.57) | POLBEPHX2ALDH1A1LMNAHPGD | |
| SCHEMBL3174558 | 0.69 | HSD11B1 (0.44) | HSD11B1POLBEPHX2ALDH1A1LMNA | |
| SCHEMBL12093413 | 0.69 | NAAA (0.38) | EPHX2ALDH1A1MEN1KMT2ADPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1960352-B1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | MERCK PATENT GMBH (DE) | 2013-08-07 | — | — | EP | claimed |
| US-8466200-B2 | 2-adamantylurea derivatives as selective 11β-HSD1 inhibitors | MERCK PATENT GMBH (DE) | 2013-06-18 | — | — | US | claimed |
| US-20120172396-A1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11B-HSD1 INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-07-05 | — | — | US | claimed |
| US-8188288-B2 | 2-adamantylurea derivatives as selective 11beta-HSD1 inhibitors | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-05-29 | — | — | US | claimed |
| US-20090227631-A1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | MERCK PATENT GESELLSCHAFT (DE) | 2009-09-10 | — | — | US | claimed |
| EP-1960352-A1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | Merck Patent GmbH (DE) | 2008-08-27 | — | — | EP | claimed |
| WO-2007068330-A1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11β-HSD1 INHIBITORS | MERCK PATENT GMBH (DE) | 2007-06-21 | — | — | WO | claimed |
| EP-1960352-B1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | MERCK PATENT GMBH (DE) | 2013-08-07 | — | — | EP | disclosed |
| US-8466200-B2 | 2-adamantylurea derivatives as selective 11β-HSD1 inhibitors | MERCK PATENT GMBH (DE) | 2013-06-18 | — | — | US | disclosed |
| US-20120172396-A1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11B-HSD1 INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-07-05 | — | — | US | disclosed |
| US-8188288-B2 | 2-adamantylurea derivatives as selective 11beta-HSD1 inhibitors | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-05-29 | — | — | US | disclosed |
| US-20090227631-A1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | MERCK PATENT GESELLSCHAFT (DE) | 2009-09-10 | — | — | US | disclosed |
| EP-1960352-A1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | Merck Patent GmbH (DE) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007068330-A1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11β-HSD1 INHIBITORS | MERCK PATENT GMBH (DE) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172396-A1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11B-HSD1 INHIBITORS | HSD11B1, HSD11B2, HSD17B1 | HSD11B1 1/4885POLB 1562/4885EPHX2 597/4885 |
| US-20090227631-A1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | HSD11B1, HSD11B2, HSD17B1 | HSD11B1 1/4885POLB 1439/4885EPHX2 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.